Navigation Links
Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting

GENEVA, Switzerland, April 27, 2007 – Merck Serono S.A. (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that Professor Fabrizio Stocchi, MD, PhD, will present the results of the first Phase III trial of safinamide as an adjunctive treatment to dopamine agonists (DA) in early Parkinson’s disease (PD) patients at the American Academy of Neurology 59th Annual Meeting to be held in Boston from 28 April to 5 May 2007.

The abstract entitled "Safinamide, a New Anti-Parkinson Agent is Effective and Well-Tolerated in Early PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-Controlled, Phase III Trial" was accepted for an oral presentation that is scheduled for Tuesday, May 1, 2007 at 3.45pm at Session S20: Movement Disorders: Essential Tremor and Medications for Parkinson’s Disease, at the Hynes Convention Center in Boston, MA, U.S.A.

Fabrizio Stocchi is a Professor of Neurology and Honorary Consultant at the IRCCS San Raffaele Rome, University "La Sapienza". He is Director of the Movement Disorders Centre and the Clinical Trial Center of the same institute.

In October 2006, Merck Serono and Newron signed a global development and commercialization agreement under which Newron has granted Merck Serono exclusive worldwide rights to develop, manufacture and commercialise safinamide in

Merck Serono 9 Chemin des Mines Corporate Media Relations Corporate Investor Relations 1202 Geneva Tel:+41 22 414 36 00 Tel:+41 22 414 36 01 Switzerland Media Relations, USA Investor Relations, USA www.merckserono.net Tel :+1 781 681 23 40 Tel:+1 781 681 25 52 News Release

Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and Restless Leg Syndrome.

###
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
4. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/9/2009)...9 Landauer, Inc. (NYSE...ronmental radiation monitoring services, today ann...dance with its long-term strategic priorities. ,... Global Physics Solutions, Inc. (GPS) and Gammadat...nt and CEO of Landauer. "These acquisitions positi...
(Date:11/9/2009).../PRNewswire-Asia-FirstCall/ -- American Oriental,B...or "AOBO"), a pharmaceutical,company dedicated to ...ure and,commercialization of a broad range of pres...day announced that it plans to release third quart...2009, after the market closes. , The Comp...
(Date:11/9/2009)...ewswire/ -- Patent attorneys Cheryl Liljestrand, P...ill showcase Stipkala LLC at the Texas Life Scienc...eld at the Institute of Molecular Medicine in Hous...es a platform for cutting-edge companies to introd...ill feature keynote addresses and panel discussion...
Breaking Medicine Technology:Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5Critical Information Network 28CiNet 28TM 29 29 Launches to Provide eLearning Solutions to Public Safety Healthcare and Industrial Operations Profes 49270 1Critical Information Network 28CiNet 28TM 29 29 Launches to Provide eLearning Solutions to Public Safety Healthcare and Industrial Operations Profes 49270 2Critical Information Network 28CiNet 28TM 29 29 Launches to Provide eLearning Solutions to Public Safety Healthcare and Industrial Operations Profes 49270 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 1Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 2Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 4Taking Aim at Relapse of Leukemia in Kids 49267 1Taking Aim at Relapse of Leukemia in Kids 49267 2
...ta ASA (OSE: ALGETA), the,Norwegian cancer therape...ind Bruland, of the Norwegian Radium Hospital, Osl... Discussion entitled,"Radium-223 in the treatment...(HRPC): Results from a randomized,placebo-control...linical Oncology,s annual meeting (1-5 June 2007, ...
...7- Results from various,clinical studies including...ed hepatocellular carcinoma, or primary liver canc...ted at the Annual,Meeting of the American Society ...une 1 - 5, 2007. , On this occasion a conference c...e 4, 2007. Starting at around 2:00 p.m. CEST,(12:0...
Other Medicine Technology:Algeta to Present Phase II Clinical Study Data for Alpharadin in,Prostate Cancer at ASCO 2
(Date:11/9/2009)...O, Calif., Nov. 9 Sutter Health, a...ther health care service providers, is donating $2... variety of local food banks will share the quarte...meals on the tables of thousands of families acros...g history of partnering with and supporting charit...
(Date:11/9/2009)...eports success with drugs that inhibit estrogen, ...wo drugs used to treat breast cancer and osteoporo...to a new study. , The drugs also cleared precan...nted the onset of cancer in mice with precancerous...and the breast cancer/osteoporosis drug raloxifene...
(Date:11/9/2009)... to fact that both eye conditions are age-related,...lthDay News) -- Cataract surgery doesn,t appear to...neration (AMD), according to a new study that chal...n loss worsens the other. , "Because both condi...ith cataract also have AMD," wrote Li Ming Dong, o...
(Date:11/9/2009)... China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Tr...unced today that Novartis, a US$41 billion interna...ke in HTDS, H1N1 Vaccine partner, Zhejiang Tianyua.... Novartis of Switzerland will begin a five-year, ...pany will dramatically increase its investment in ...
(Date:11/9/2009)...nal Comprehensive Cancer Network (NCCN) has posted...ls a draft paradigm for near-term comparative effe... data. The document introduces the NCCN Comparativ...rocess that compares the risk-versus-benefit of di...Clinical Practice Guidelines in Oncology(TM). The ...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4
... Jan. 5 Locum Leaders,( http://www.locumleaders.c...m,specializing in temporary medical staffing, know...009. The company,s positive outlook is fueled by,i...nding, we predict strong quarterly growth in our,b...
... Universal Music Enterprises (UMe) , a division o...ic company, and Jake Steinfeld, the iconic entrepr...onal fitness training industry with his Body By J...egory-specific workout music. The announcement was...
... Jan. 5 Kaiser Permanente announced today,that it...ed over three years,to sponsor the IHI Open School...itute for Healthcare Improvement. , Funding fo...roud of the fact that over the years, Kaiser Perma...
...Facing Generic Competition Will be Dropped or Push...g to a New Report from Decision Resources , , WAL...the world,s leading research and advisory firms fo...y by indication, affording branded AEDs protection...
... The Flat Belly Diet! reduced dangerous,visceral ...to a new study by,the Yale University Prevention...Researchers followed nine overweight women on the ... heart health such as,cholesterol, blood pressure,...
...tories of sudden cardiac arrest , , MONDAY...t stopped beating on July 20, 2007. Just like that...ate University, doing normal laps," recalled Babco...ltz,s heart stopped on July 20, 2009. "I was sitti...
Other Medicine News:Health News:Physician Staffing Trends and Hospitalist Jobs Fuel Growth at Locum Leaders 2Health News:Universal Music Enterprises (UMe) and Body By Jake Global Create the World's First Digital Fitness Music Label 2Health News:Universal Music Enterprises (UMe) and Body By Jake Global Create the World's First Digital Fitness Music Label 3Health News:Universal Music Enterprises (UMe) and Body By Jake Global Create the World's First Digital Fitness Music Label 4Health News:Universal Music Enterprises (UMe) and Body By Jake Global Create the World's First Digital Fitness Music Label 5Health News:Kaiser Permanente Provides Seed Funding to the Institute for Healthcare Improvement's New Open School for Health Professions 2Health News:Kaiser Permanente Provides Seed Funding to the Institute for Healthcare Improvement's New Open School for Health Professions 3Health News:Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients 2Health News:Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients 3Health News:Photo: New Yale University Prevention Research Center Study Finds Flat Belly Diet! Reduced Dangerous Visceral Belly Fat by 33% 2Health News:When the Heart Stops Beating 2
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: